drugset / Trial / NCT03812783

HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC

NCT03812783

Phase 2 Unknown 100 enrolled Sun Yat-sen University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, 5-fluorouracil and leucovorin plus sorafenib compared with HAIC of irinotecan, oxaliplatin, 5-fluorouracil and leucovorin plus sorafenib in patients with advanced hepatocellular carcinoma (HCC)

Timeline

Start
2018-11-05
Primary completion
2019-12-01
Completion
2019-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Irinotecan Small molecule
Background Leucovorin Small molecule
Background Oxaliplatin Small molecule
Background Sorafenib Small molecule
Background fluorouracil Small molecule